BUY
It had a big run during Covid because of Covid testing. However, since then, shares have fallen more than 13% though that's much better than the rest of the market. He's confident in it: it'll face much easier comps this year, and they can be a leading player in women's health (it's the start of Breast Cancer Awareness Month).
Healthcare

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock opinion & get signals
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Apr 26/22, Down 3.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with HOLX has triggered its stop at $68. To remain disciplined, we recommend covering the position at this time.
Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly We again reiterate HOLX, a $17 billion market cap developer of medical diagnostics imaging systems of products as a TOP PICK. Earnings will be released soon and analysts have been revising up expectations. Many medical device companies have been negatively impacted by the pandemic as it slowed demand for some of their products, but analysts believe HOLX should still be benefitting on most of its products. Nevertheless, we recommend keeping the stop tight at $68, looking to achieve $85 -- upside potential of 20%. Yield 0% (Analysts’ price target is $85.09)
Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Feb 24/22, Up 7.8%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with HOLX is progressing well. To remain disciplined, we now recommend trailing up the stop (from $60) to $68.
Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly We again reiterate this $17 billion market cap developer of medical diagnostics imaging systems of products. Recently reported earnings beat analyst expectations by 85%. Although revenues were down on the year due to the pandemic, they too beat expectations. It trades at 11x earnings compared to peers at 20x. We like that cash reserves continue to grow, while the company buys back shares. We would buy this with a $60 stop loss, looking to achieve $85 -- upside potential over 20%. Yield 0% (Analysts’ price target is $85.09)
Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly On the back of continued performance growth, we again reiterate HOLX as a TOP PICK. The manufacturer of medical equipment and diagnostic devices including COVID-19 test kits and women's health early detection and treatment is increasing Q1 revenue expectations well above previous guidance. It trades at 10x earnings compared to peers at 18x. Previously reported earnings beat analyst expectations by over 55% and the company maintains an astounding 57% ROE. We like they also continue to increase cash reserves, while paying down debt and buying back shares. EPS growth will naturally slow somewhat as the pandemic wave crests, but the company continues to have a good pipeline of projects. We recommend trailing up the stop (from $60) to $64, looking to achieve $86.50 - upside potential over 20%. Yield 0%
Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly We reiterate HOLX as a TOP PICK. The company manufactures medical equipment and diagnostic devices including COVID-19 test kits and women's health early detection and treatment. It trades at 9x earnings compared to peers at 32x. EPS growth will naturally slow somewhat as the pandemic wave crests, but the company continues to have a good pipeline of projects. We would buy this with a stop loss at $60, looking to achieve $87 - upside potential over 20%. Yield 0% (Analysts’ price target is $86.93)
Healthcare
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly HOLX manufactures medical equipment and diagnostic devices including COVID-19 test kits. Sales were recently reported up almost 90% and management guidance calls for revenue to double over the year to over $1.5 billion. Trading at 11x earnings, it is good value here. We would buy this with a stop-loss at $56, looking to achieve $89 -- upside potential of 25%. Yield 0% (Analysts’ price target is $89.08)
Healthcare
BUY
They make diagnostics equipment, imaging systems and surgical products mostly for women's health. They now are very active in Covid testing. last week, they reported a blow-out quarter (diagnostic sales up 262% YOY) with good guidance for the current quarter but also post-Covid. They've made big investments in their breast and surgical divisions. The stock has since run up $10, but it has more room to run.
Healthcare
Showing 1 to 9 of 9 entries
  • «
  • 1
  • »

Hologic(HOLX-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 3

Stockchase rating for Hologic is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Hologic(HOLX-Q) Frequently Asked Questions

What is Hologic stock symbol?

Hologic is a American stock, trading under the symbol HOLX-Q on the NASDAQ (HOLX). It is usually referred to as NASDAQ:HOLX or HOLX-Q

Is Hologic a buy or a sell?

In the last year, 3 stock analysts published opinions about HOLX-Q. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Hologic.

Is Hologic a good investment or a top pick?

Hologic was recommended as a Top Pick by on . Read the latest stock experts ratings for Hologic.

Why is Hologic stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Hologic worth watching?

3 stock analysts on Stockchase covered Hologic In the last year. It is a trending stock that is worth watching.

What is Hologic stock price?

On 2022-12-02, Hologic (HOLX-Q) stock closed at a price of $76.5.